Search
Healthcare-affiliated professional membership
You don't need to be scientific researcher or a physician to join our vibrant community.
Read moreHighlights of Past EHA (HOPE) Latin America 2021
For the third edition of the Highlights of Past EHA (HOPE) Latin America (LA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.
Read moreEHA-SPSHTM joint membership
Save money and time by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreWhat to expect from European Affairs at EHA2024
European Affairs gives a voice to hematology professionals in Europe. The department ensures that the interests of EHA members are duly represented in policy, regulatory and scientific areas and networks.
Read moreHematology Tutorials
Hematology Tutorials are courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders.
Read moreDutch scientists propose algorithm to keep drugs affordable and accessible
May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.
Read moreEHA-HSH joint membership
Save money and time by becoming a joint member of EHA and the Hellenic Society of Haematology. We've joined forces with the Hellenic Society of Haematology (HSH) to offer a special joint membership deal.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.